TIV helps to commercialize a novel enzyme technology for treating cardiovascular disease

TIV helps to commercialize a novel enzyme technology for treating cardiovascular disease

Tambourine Innovation Ventures (TIV) partnered with a leading university to advance the commercialization of a groundbreaking enzyme-based therapeutic designed to address cardiovascular disease. The collaboration focused on strengthening the client’s ability to secure and manage NIH SBIR funding—an area in which they sought additional expertise. This work falls under TIV’s partnership with the Wyoming Small Business Development Center (SBDC), where “entrepreneurs help entrepreneurs”. In this unique case, the client’s innovation targeted a critical unmet need in cardiovascular care: therapies that can directly remodel pathological tissue after heart injury, something current drugs cannot achieve. Their approach leveraged an FDA-approved enzyme technology repurposed for cardiovascular applications, offering the potential to transform outcomes for patients with heart failure and related conditions.

TIV provided a comprehensive suite of services to accelerate this opportunity. Our team first conducted in-depth funding research, identifying NIH SBIR opportunities aligned with the client’s technology platform and strategic goals. We then led the proposal development process drafting, refining, and preparing detailed applications that articulated the project’s scientific aims, clinical potential, and commercialization pathway. This included developing compelling narratives, budgets, and supporting documentation to meet NIH’s rigorous standards. Our team worked closely with the client through multiple rounds of review and revision to ensure the proposal aligned with both NIH criteria and the client’s vision. TIV also handled submission logistics, ensuring compliance with procedural requirements and timely filing. Beyond the immediate proposal, we engaged in hands-on coaching with the client’s team—building their internal grant-writing and management capabilities to support long-term growth.

Through this collaboration, the client successfully submitted their NIH SBIR application, positioning their novel enzyme platform for advancement toward clinical validation. The engagement also established a commercialization pathway for bringing their therapy to market, including early use cases and regulatory strategies.